News & Press: Latest News

MDMA Statement on HHS Task Force Report on Pain Management Best Practices

Thursday, May 30, 2019  
Share |

MDMA Statement on HHS Task Force Report on Pain Management Best Practices


WASHINGTON, DC – Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), issued the following statement today on the report issued by the Department of Health and Human Services’ (HHS) Pain Management Task Force:


“MDMA applauds the work of the HHS Pain Management Best Practices Inter-Agency Task Force culminating in the release of a report today that provides recommendations and best practices for patients suffer from acute, transitional and chronic pain symptoms. There are more than 200 medical devices currently in the marketplace with components for treating pain and many more innovations in development, and this report recognizes the critical role of our industry in working to solve the challenge of pain management.


“We appreciate the Task-Force Chair, HHS Chief Medical Officer Dr. Vanila Singh, and all the task force members for not only highlighting many of these medical technologies, but for also acknowledging some of the barriers that prevent patient access to these therapies. All too often, patients are denied access to evidence-based, FDA approved or cleared non-opioid medical device pain treatment alternatives due to reimbursement challenges and unnecessary administrative burdens.  MDMA also agrees with the task force that there is a need for patient and provider education in the complete spectrum of non-opioid pain management solutions.


“MDMA looks forward to continue working with the task force members, policy makers and all stakeholders to implement policy recommendations in the report that allow for increased access to innovative medical technologies that help patients suffering from pain.”